(Q36301573)

13 August 2017

1 reference

title

Insulin-sensitisers in the treatment of polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

13 August 2017

main subject

1 reference

1 reference

Helena J Teede

1

1 reference

13 August 2017

C Meyer

series ordinal

2

1 reference

13 August 2017

R J Norman

series ordinal

3

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

Expert Opinion on Pharmacotherapy

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

14

1 reference

13 August 2017

page(s)

2419-2427

1 reference

The prevalence and features of the polycystic ovary syndrome in an unselected population

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Laparoscopic treatment of polycystic ovaries: is it time to relinquish the procedure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Metformin and gestational diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Anti-androgens for the treatment of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Recent advances in the treatment of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Medical Consequences of Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Effect of hypertension therapy with the angiotensin-converting enzyme inhibitor lisinopril on hyperandrogenism in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Mortality of women with polycystic ovary syndrome at long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Effect of metformin on mouse embryo development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2419

10.1517/14656566.6.14.2419

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference